|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 人工肩关节表面置换术的应用显示文摘 | 鲁宁 Edward V Craig | 2010 | 中华关节外科杂志(电子版)2010，4，5： | 8 |
| 2 | Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences显示文摘 | Edward V Loftus | 2004 | Gastroenterology2004，，6： | 7 |
| 3 | Approach to medical therapy in perianal Crohn’s disease显示文摘Perianal Crohn’s disease remains a challenging condition to treat and can have a substantial negative impact on quality of life.It often requires combined surgical and medical interventions.Anti-tumor necrosis factor(anti-TNF)therapy,including infliximab and adalimumab,remain preferred medical therapies for perianal Crohn’s disease.Infliximab has been shown to be efficacious in improving fistula closure rates in randomized controlled trials.Clinicians can be faced with a number of questions relating to the optimal use of anti-TNF therapy in perianal Crohn’s disease.Specific issues include evaluation for the presence of perianal sepsis,the treatment target of therapy,the ideal time to commence treatment,whether additional medical therapy should be used in conjunction with anti-TNF therapy,and the duration of treatment.This article will discuss key studies which can assist clinicians in addressing these matters when they are considering or have already commenced anti-TNF therapy for the treatment of perianal Crohn’s disease.It will also discuss current evidence regarding the use of vedolizumab and ustekinumab in patients who are failing to achieve a response to anti-TNF therapy for perianal Crohn’s disease.Lastly,new therapies such as local injection of mesenchymal stem cell therapy will be discussed. | Abhinav Vasudevan David H Bruining Edward V Loftus Jr William Faubion Eric C Ehman Laura Raffals | 2021 | World Journal of Gastroenterology2021，27，25： | 4 |
| 4 | A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia—a preliminary report 1 1 Original Contributions is coordinated by John A. Marx , MD, of Carolinas Medical Center, Charlotte, North Carolina显示文摘 | David Bar–Or Edward Lau James V Winkler | 2000 | Journal of Emergency Medicine2000，，4： | 3 |
| 5 | Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors显示文摘AIM:To evaluate systemic treatment choices in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors(PNETs)and provide consensus treatment recommendations.METHODS:Systemic treatment options for pancreatic neuroendocrine tumors have expanded in recent years to include somatostatin analogs,angiogenesis inhibitors,inhibitors of mammalian target of rapamycinand cytotoxic agents.At this time,there is little data to guide treatment selection and sequence.We therefore assembled a panel of expert physicians to evaluate systemic treatment choices and provide consensus treatment recommendations.Treatment appropriateness ratings were collected using the RAND/UCLA modified Delphi process.After studying the literature,a multidisciplinary panel of 10 physicians assessed the appropriateness of various medical treatment scenarios on a 1-9 scale.Ratings were done both before and after an extended discussion of the evidence.Quantitative measurements of agreement were made and consensus statements developed from the second round ratings.RESULTS:Specialties represented were medical and surgical oncology,interventional radiology,and gastroenterology.Panelists had practiced for a mean of15.5 years(range:6-33).Among 202 rated scenarios,disagreement decreased from 13.2%(26 scenarios)before the face-to-face discussion of evidence to 1%(2)after.In the final ratings,46.5%(94 scenarios)were rated inappropriate,21.8%(44)were uncertain,and30.7%(62)were appropriate.Consensus statements from the scenarios included:(1)it is appropriate to use somatostatin analogs as first line therapy in patients with hormonally functional tumors and may be appropriate in patients who are asymptomatic;(2)it is appropriate to use everolimus,sunitinib,or cytotoxic chemotherapy therapy as first line therapy in patients with symptomatic or progressive tumors;and(3)beyond first line,these same agents can be used.In patients with uncontrolled secretory symptoms,octreotide LAR doses can be titrated up to 60 mg every4 wk or up to 40 mg every 3 or 4 wk.CONCLUSION:Using the Delphi process allowed physician experts to systematically obtain a consensus on the appropriateness of a variety of medical therapies in patients with PNETs. | Jonathan R Strosberg George A Fisher Al B Benson Lowell B Anthony Bulent Arslan John F Gibbs Edward Greeno Renuka V Iyer Michelle K Kim William J Maples Philip A Philip Edward M Wolin Dasha Cherepanov Michael S Broder | 2015 | World Journal of Gastroenterology2015，21，8： | 2 |
| 6 | Perigastric extraskeletal Ewing's sarcoma: A case report显示文摘Ewing's sarcoma (ES) is a neoplasm of undifferentiated small round cells, which occurs in the bones and deep soft tissues of children and adolescents. We present a rare case of a 44-year-old woman with gastric ES presenting with epigastric pain and weight loss. Ultrasound and computed tomography scans indicated a solid/cystic mass in the pancreatic tail. At laparotomy, the tumor was found attached to the posterior surface of the stomach, completely free from the pancreas, with no lymphadenopathy or local metastases. The polynodal, partly pseudocystic, dark-red soft tumor was excised. Histopathology revealed an anaplastic small-round-cell tumor with strong membranous CD99 immunoexpression. Additionally, there was patchy immunostaining for S-100 protein, vimentin, protein gene product (PGP) 9.5 and neuron-specifi c enolase, and weak focal CD117 cytoplasmic immunoreactivity. The patient had no adjuvant chemotherapy; her postoperative recovery was uneventful, and she remains symptom-free, and without any sign of recurrence at 20 mo. To the best of our knowledge, this is only the third ever case of gastric ES. | Radoje B Colovic Nikica M Grubor Marjan T Micev Slavko V Matic Henry Dushan Edward Atkinson Stojan M Latincic | 2009 | World Journal of Gastroenterology2009，15，2： | 2 |
| 7 | Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial显示文摘 | Edward B Garon Tudor-Eliade Ciuleanu Oscar Arrieta Kumar Prabhash Konstantinos N Syrigos Tuncay Goksel Keunchil Park Vera Gorbunova Ruben Dario Kowalyszyn Joanna Pikiel Grzegorz Czyzewicz Sergey V Orlov Conrad R Lewanski Michael Thomas Paolo Bidoli Shaker | 2014 | The Lancet2014，，： | 2 |
| 8 | Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease显示文摘 | Uma Mahadevan Edward V Loftus William J Tremaine William J Sandborn | 2002 | The American Journal of Gastroenterology2002，，4： | 2 |
| 9 | A segmentation algorithm for noisy images: design and evaluation显示文摘 | Xu Y Olman V Edward C U | 1998 | Pattern Recognition Letters1998，19，13： | 1 |
| 10 | Diagnosis and management of pituitary abscess:a review of twenty-four cases显示文摘 | EDWARD G V MITHCHEL S BERGEN | 2001 | J Neurosurg2001，95，： | 1 |
| 11 | SCOPE:a probabilistic model for scoring tandem mass spectra against a peptide database显示文摘 | Bafna V Edwards N | 2001 | Bioinformatics2001，17，： | 1 |
| 12 | Improvement After Constraint Induced Movement Therapy Is Independent of Infarct Location in Chronic Stroke Patients显示文摘 | Gauthier Lynne V MA Taub Edward PhD | 2009 | Stroke2009，40，7： | 1 |
| 13 | Signal transducer and activator of transcription (STAT) 3 inhibition delays the onset of lupus nephritis in MRL/lpr mice显示文摘 | Edwards LJ Mizui M Kyttaris V | 2015 | Clin I mmunol2015，158，2： | 1 |
| 14 | OMEGA EP high-energy petawatt laser: progress and prospects显示文摘 | D N Maywar J H Kelly L J Waxer S F B Morse I A Begishev J Bromage C Dorrer J L Edwards L Folnsbee M J Guardalben S D Jacobs R Jungquist T J Kessler R W Kidder B E Kruschwitz S J Loucks J R Marciante R L McCrory D D Meyerhofer A V Okishev J B Oliver G Pien | 2008 | Journal of Physics: Conference Series2008，，3： | 1 |
| 15 | N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis显示文摘 | Elena R William R Taylor Edward V | 2002 | The American Journal of Gastroenterology2002，97，7： | 1 |
| 16 | Syntheses,calcium channel modulation effects,and nitric oxide releasing studies of O2-alkyl-1-(pyrrolidin)-1,4-dihydro-2,6-dimethyl-3-nitropyridine-5-carboxylates显示文摘 | CARLOS V DEAN V EDWARDS E K | 2003 | Drug Dev Res2003，60，3： | 1 |
| 17 | The impact of speed of processing training on cognitive and everyday perform- ance 显示文摘 | Edwards J D Wadley V G Vance D E | 2005 | Azing Ment Health2005，9，3： | 1 |
| 18 | Community genomics among stratified microbial assemblages in the ocean's interior显示文摘 | DeLong E F Preston C M Mincer T Rich V Hallam S J Frigaard N U Martinez A Sullivan M B Edwards R Brito B R Chisholm S W Karl D M | | 0，，5760： | 1 |
| 19 | Clinical efficacy of specific immunotheraph to cat dan- der: a double-blind placebo-controlled trial 显示文摘 | VARNEY V A EDWARDS J TABBAH K | 1997 | Clin Exp Allergy1997，27，： | 1 |
| 20 | Root characteristics and growth potential of container and bare-root seedlings of red oak (Quercus rubra L ) in Ontario, Canada显示文摘 | Edward R W Kristjan C V Andrew P | 2007 | New forests2007，34，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员